## Umut Kalyoncu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1019074/publications.pdf

Version: 2024-02-01

92	1,381	19	34
papers	citations	h-index	g-index
93	93	93	1834
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Annals of the Rheumatic Diseases, 2014, 73, 1012-1019.	0.9	314
2	Amyloidosis and its related factors in Turkish patients with familial Mediterranean fever: a multicentre study. Rheumatology, 2014, 53, 741-745.	1.9	96
3	Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: Data from a large multicenter cohort. Journal of Autoimmunity, 2016, 69, 59-63.	6.5	62
4	Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. Journal of Rheumatology, 2007, 34, 1540-4.	2.0	53
5	Nationwide Experience With Offâ€Label Use of Interleukinâ€1 Targeting Treatment in Familial Mediterranean Fever Patients. Arthritis Care and Research, 2018, 70, 1090-1094.	3.4	48
6	Fatigue in psoriatic arthritis–Âa cross-sectional study of 246Âpatients from 13Âcountries. Joint Bone Spine, 2016, 83, 439-443.	1.6	47
7	Familial Mediterranean fever is associated with a wide spectrum of inflammatory disorders: results from a large cohort study. Rheumatology International, 2020, 40, 41-48.	3.0	45
8	The Reporting of Patient-reported Outcomes in Studies of Patients with Rheumatoid Arthritis: A Systematic Review of 250 Articles. Journal of Rheumatology, 2016, 43, 1300-1305.	2.0	41
9	Familial Mediterranean Fever and Central Nervous System Involvement. Medicine (United States), 2010, 89, 75-84.	1.0	40
10	Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set. RMD Open, 2016, 2, e000217.	3.8	35
11	Impact of Having Family History of Psoriasis or Psoriatic Arthritis on Psoriatic Disease. Arthritis Care and Research, 2020, 72, 63-68.	3.4	35
12	The Psoriatic Arthritis Registry of Turkey: results of a multicentre registry on 1081 patients. Rheumatology, 2017, 56, 279-286.	1.9	29
13	Comparison of early versus late onset familial Mediterranean fever. International Journal of Rheumatic Diseases, 2018, 21, 880-884.	1.9	25
14	Factors Affecting the Sexual Satisfaction of Patients with Rheumatoid Arthritis and Ankylosing Spondylitis. Sexuality and Disability, 2010, 28, 223-232.	1.0	24
15	Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. Journal of Rheumatology, 2016, 43, 965-969.	2.0	24
16	Axial psoriatic arthritis: the impact of underdiagnosed disease on outcomes in real life. Clinical Rheumatology, 2018, 37, 3443-3448.	2.2	24
17	Treatment Satisfaction, Patient Preferences, and the Impact of Suboptimal Disease Control in a Large International Rheumatoid Arthritis Cohort: SENSE Study. Patient Preference and Adherence, 2021, Volume 15, 359-373.	1.8	24
18	The distribution of MEFV mutations in Turkish FMF patients: multicenter study representing results of Anatolia. Turkish Journal of Medical Sciences, 2019, 49, 472-477.	0.9	23

#	Article	IF	CITATIONS
19	Predictors of persistent inflammation in familial Mediterranean fever and association with damage. Rheumatology, 2021, 60, 333-339.	1.9	21
20	Accurate diagnosis of acute abdomen in FMF and acute appendicitis patients: how can we use procalcitonin?. Clinical Rheumatology, 2007, 26, 2059-2062.	2.2	20
21	Inflammatory bowel diseases and Takayasu's arteritis: coincidence or association?. International Journal of Rheumatic Diseases, 2016, 19, 814-818.	1.9	18
22	Proposal for a simple algorithm to differentiate adult-onset Still's disease with other fever of unknown origin causes: a longitudinal prospective study. Clinical Rheumatology, 2019, 38, 1699-1706.	2.2	18
23	Increased serum vitamin B12 levels are associated with adult-onset Still's disease with reactive macrophage activation syndrome. Joint Bone Spine, 2010, 77, 131-134.	1.6	16
24	Clinical features and disease course of neurological involvement in Behcet's disease: HUVAC experience. Multiple Sclerosis and Related Disorders, 2020, 38, 101512.	2.0	15
25	COVID-19 Among Patients With Inflammatory Rheumatic Diseases. Frontiers in Immunology, 2021, 12, 651715.	4.8	15
26	Performances of inflammatory back pain criteria in axial psoriatic arthritis. Rheumatology, 2017, 56, 2031-2032.	1.9	14
27	MEFV mutation frequency and effect on disease severity in ankylosing spondylitis. Turkish Journal of Medical Sciences, 2014, 44, 203-207.	0.9	13
28	Colchicine intolerance in FMF patients and primary obstacles for optimal dosing. Turkish Journal of Medical Sciences, 2020, 50, 1337-1343.	0.9	13
29	Alteration of the microRNA expression profile in familial Mediterranean fever patients. Clinical and Experimental Rheumatology, 2017, 35 Suppl 108, 90-94.	0.8	13
30	Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience. Turkish Journal of Medical Sciences, 2021, 51, 297-308.	0.9	11
31	Predictors of mortality in rheumatoid arthritis-associated lung disease: A retrospective study on ten years. Joint Bone Spine, 2021, 88, 105133.	1.6	11
32	Uveitis-related Factors in Patients With Spondyloarthritis: TReasure Real-Life Results. American Journal of Ophthalmology, 2021, 228, 58-64.	3.3	10
33	Exon 2: Is it the good police in familial mediterranean fever?. European Journal of Rheumatology, 2019, 6, 33-36.	0.6	10
34	Rituximab Therapy in Renal Amyloidosis Secondary to Rheumatoid Arthritis. Biomolecules, 2018, 8, 136.	4.0	9
35	Evaluation of Vitamin B12 Deficiency and Associated Factors in Patients With Systemic Sclerosis. Journal of Clinical Rheumatology, 2018, 24, 250-254.	0.9	8
36	Disease characteristics of psoriatic arthritis patients may differ according to age at psoriasis onset: cross-sectional data from the Psoriatic Arthritis-International Database. Clinical and Experimental Rheumatology, 2021, 39, 532-536.	0.8	8

3

#	Article	IF	CITATIONS
37	What does evidence-based medicine tell us about treatments for different subtypes of psoriatic arthritis? A systematic literature review on randomized controlled trials. Rheumatology Advances in Practice, 2018, 2, rkx019.	0.7	7
38	Methodology of a new inflammatory arthritis registry: TReasure. Turkish Journal of Medical Sciences, 2018, 48, 856-861.	0.9	7
39	Familial Mediterranean fever-associated infertility and underlying factors. Clinical Rheumatology, 2020, 39, 255-261.	2.2	7
40	Budd–Chiari syndrome in Behçet's disease: a retrospective multicenter study. Clinical Rheumatology, 2021, , 1.	2.2	7
41	Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice. Biologics: Targets and Therapy, 2018, Volume 12, 1-9.	3.2	6
42	Change in PsAID-12 scores in patients continuing or discontinuing anti-TNF treatments in psoriatic arthritis: results from the HUR-BIO biologic registry. Clinical Rheumatology, 2019, 38, 1187-1192.	2.2	6
43	Current Smoking Is Increased in Axial Psoriatic Arthritis and Radiographic Sacroiliitis. Journal of Rheumatology, 2020, 47, 1354-1358.	2.0	6
44	Temporomandibular disorders in ankylosing spondylitis: a cross-sectional, monocentric study. Rheumatology International, 2020, 40, 933-940.	3.0	6
45	Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic. Turkish Journal of Medical Sciences, 2021, 51, 1615-1623.	0.9	6
46	Rare occupational cause of nasal septum perforation: Nickel exposure. International Journal of Occupational Medicine and Environmental Health, 2017, 30, 963-967.	1.3	6
47	Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data. Clinical and Experimental Rheumatology, 0, , .	0.8	6
48	Imaging modalities used in diagnosis and follow-up of patients with Takayasu's arteritis. Turkish Journal of Medical Sciences, 2021, 51, 224-230.	0.9	5
49	Comparison of cardiovascular, cancer and herpes zoster risk of tofacitinib versus etanercept: single-centre observational study. Rheumatology, 2022, 61, e267-e269.	1.9	5
50	Cancer incidence in familial Mediterranean fever patients: a retrospective analysis from central Anatolia. Rheumatology International, 2019, 39, 1045-1051.	3.0	4
51	Abnormal retinal microvasculature found in active rheumatoid arthritis:a different perspective of microvascular health. Turkish Journal of Medical Sciences, 2019, 49, 20-26.	0.9	4
52	Anti-interleukin-6 (tocilizumab) therapy in Takayasu's arteritis: real-life experience. Turkish Journal of Medical Sciences, 2020, 50, 31-36.	0.9	4
53	Avascular necrosis less frequently found in systemic lupus erythematosus patients with the use of alternate day corticosteroid. Turkish Journal of Medical Sciences, 2020, 50, 219-224.	0.9	4
54	PsART-ID inception cohort: clinical characteristics, treatment choices and outcomes of patients with psoriatic arthritis. Rheumatology, 2021, 60, 1755-1762.	1.9	4

#	Article	IF	CITATIONS
55	Vasculitis during certolizumab pegol and secukinumab treatment: Report of two cases. Dermatologic Therapy, 2021, 34, e15007.	1.7	4
56	Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study. Clinical Rheumatology, 2022, 41, 85-94.	2.2	4
57	Rubinstein-Taybi syndrome and familial Mediterranean fever in a single patient: two distinct genetic diseases located on chromosome 16p13.3. Journal of the National Medical Association, 2006, 98, 1692-3.	0.8	4
58	Alterations of von Willebrand Factor and Ristocetin Cofactor Activity During Atrial Fibrillation. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 103-108.	1.7	3
59	What are the main barriers to achieve minimal disease activity in psoriatic arthritis in real life?. Clinical and Experimental Rheumatology, 2019, 37, 808-812.	0.8	3
60	Disease activity at the entheses and joints are correlated in psoriatic arthritis when explored with ultrasound. Clinical and Experimental Rheumatology, 2022, 40, 44-48.	0.8	3
61	Is the PET/CT first choice for differential diagnosis of fever of FUO/IUO?. Annals of the Rheumatic Diseases, 2018, 77, e82-e82.	0.9	2
62	Two cases of glutaric aciduria type II: how to differentiate from inflammatory myopathies?. Acta Clinica Belgica, 2019, 74, 451-455.	1.2	2
63	Pregnancy outcomes in partners of male ankylosing spondylitis patients treated with anti-tumour necrosis factor-α biologics: real-life results from a single-centre cross-sectional study. Rheumatology International, 2020, 40, 1501-1507.	3.0	2
64	The frequency of Achilles and plantar calcaneal spurs in gout patients. Turkish Journal of Medical Sciences, 2021, 51, 1841-1848.	0.9	2
65	Patient characteristics and minimal disease activity in psoriatic arthritis: a transcontinental comparison. Clinical Rheumatology, 2021, 40, 3169-3174.	2.2	2
66	Factors associated with damage in patients with familial Mediterranean fever. Clinical and Experimental Rheumatology, 2020, 38 Suppl 127, 42-48.	0.8	2
67	Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 85-94.	0.8	2
68	The reliability, validity, and responsiveness of Cognitive Exercise Therapy Approach: Biopsychosocial Questionnaire for patients with psoriatic arthritis. Rheumatology International, 2022, 42, 1973-1981.	3.0	2
69	Appendectomy history is associated with severe disease and colchicine resistance in adult familial Mediterranean fever patients. Turkish Journal of Medical Sciences, 2021, 51, 1706-1711.	0.9	1
70	Phenotypic characterisation of Familial Mediterranean Fever patients harboring variants of uncertain significance. Turkish Journal of Medical Sciences, 2021, 51, 1695-1701.	0.9	1
71	In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?. Rheumatology International, 2021, 41, 1915-1924.	3.0	1
72	Anxiety levels before biologic initiation and changes with treatment in patients with psoriatic arthritis: HUR-BIO biologic registry results. Clinical Rheumatology, 2022, , 1.	2.2	1

#	Article	IF	CITATIONS
73	Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data. Clinical and Experimental Rheumatology, 2021, 39, 852-858.	0.8	1
74	Disease activity at the entheses and joints are correlated in psoriatic arthritis when explored with ultrasound. Clinical and Experimental Rheumatology, $2021,  ,  .$	0.8	1
75	Evaluation of Intravenous Immunoglobulin G treatment in Outpatients Rheumatology Practice. Acta Medica, 0, , 1-8.	0.2	1
76	Comment on: Monitoring Achilles enthesitis in ankylosing spondylitis during TNF-Â antagonist therapy: an ultrasound study: reply. Rheumatology, 2010, 49, 1419-1420.	1.9	0
77	Data of indirect immunofluorescence labeling of the mouse brain sections with sera from SLE and MS patients. Data in Brief, 2017, 15, 170-173.	1.0	0
78	Large joint and lower extremity involvement have higher impact on disease outcomes in oligoarticular psoriatic arthritis. International Journal of Rheumatic Diseases, 2020, 23, 1094-1099.	1.9	0
79	Punched-out erosions in sacroiliac joints. Clinical Rheumatology, 2021, 40, 3859-3860.	2.2	0
80	c-ANCA positivity in a patient with relapsing polychondritis: Co-incidence or not? A case and review of the literature. Ulusal Romatoloji Dergisi, 2021, 13, 88-90.	0.0	0
81	Comparison of Diagnostic Subgroup Survivals of Patients Who Admitted for Fever of Unknown Etiology Evaluation: Long-term Results of Single-centre, Prospective Study. Flora: the Journal of Infectious Diseses and Clinical Microbiology = Infeksiyon Hastalıkları Ve Klinik Mikrobiyoloji Dergisi, 2019. 24. 199-206.	0.1	0
82	Psoriasis Symptom Inventory (PSI) as a patient-reported outcome in mild psoriasis: Real life data from a large psoriatic arthritis registry. European Journal of Rheumatology, 2020, 7, 64-67.	0.6	0
83	The evaluation of rheumatoid arthritis patients with knee and hip prosthesis: HURBIO biological registry. Ulusal Romatoloji Dergisi, 2020, 12, 39-44.	0.0	0
84	Evaluation of relationship between peripheral neuropathy and digital ulcer formation in patients with systemic sclerosis. Ulusal Romatoloji Dergisi, 2020, 12, 76-82.	0.0	0
85	Conventional Synthetic Dmards in Psoriatic Arthritis: Changing Practice in Biologic Era; Real-Life Results from HURBIO-PsA Registry. Acta Medica, 0, , 1-7.	0.2	0
86	Predictors of drug retention and treatment response in axial spondyloarthritis patients treated with certolizumab: real-life results from the HURBIO registry. Clinical and Experimental Rheumatology, 2020, 38, 609-614.	0.8	0
87	Disease characteristics of psoriatic arthritis patients may differ according to age at psoriasis onset: cross-sectional data from the Psoriatic Arthritis-International Database. Clinical and Experimental Rheumatology, 2021, 39, 532-536.	0.8	0
88	Is the impact of biologic agents in enteropathic spondylitis different from other spondylitis? Real life data from the HUR-BIO Registry. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
89	Can we predict transition from psoriasis to psoriatic arthritis?. Ulusal Romatoloji Dergisi, 2021, 13, 121-128.	0.0	0
90	The influence of obesity on biological agents treatment response in psoriatic arthritis: HUR-BIO real life results. Ulusal Romatoloji Dergisi, 2021, 13, 107-115.	0.0	0

#	Article	lF	CITATIONS
91	Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data Clinical and Experimental Rheumatology, 2022, , .	0.8	O
92	Tuberculin skin test before biologic and targeted therapies: does the same rule apply for all?. Rheumatology International, 2022, 42, 1797-1806.	3.0	0